SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Naruke T, Tsuchiya R, Kondo H, Asamura H, Nakayama H. Implications of staging in lung cancer. Chest. 1997; 112: 242S248S.
  • 2
    Naruke T, Tsuchiya R, Kondo H, Asamura H. Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann Thorac Surg. 2001; 71: 17591764.
  • 3
    Turner RR, Ollila DW, Krasne DL, Giuliano AE. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg. 1997; 226: 271276.
  • 4
    Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995; 222: 394399.
  • 5
    Ogawa Y, Ishikawa T, Sawada T, et al. Thoracoscopic internal mammary sentinel node biopsy for breast cancer. Surg Endosc. 2003; 17: 315319.
  • 6
    Liptay MJ, Masters GA, Winchester DJ, et al. Intraoperative radioisotope sentinel lymph node mapping in non-small cell lung cancer. Ann Thorac Surg. 2000; 70: 384389.
  • 7
    Liptay MJ, Grondin SC, Fry WA, et al. Intraoperative sentinel lymph node mapping in non-small-cell lung cancer improves detection of micrometastases. J Clin Oncol. 2002; 20: 19841988.
  • 8
    Nomori H, Horio H, Naruke T, Orikasa H, Yamazaki K, Suemasu K. Use of technetium-99m tin colloid for sentinel lymph node identification in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2002; 124: 486492.
  • 9
    Melfi FM, Chella A, Menconi GF, et al. Intraoperative radioguided sentinel lymph node biopsy in non-small cell lung cancer. Eur J Cardiothorac Surg. 2003; 23: 214220.
  • 10
    Schmidt FE, Woltering EA, Webb WR, Garcia OM, Cohen JE, Rozans MH. Sentinel nodal assessment in patients with carcinoma of the lung. Ann Thorac Surg. 2002; 74: 870874.
  • 11
    Yoshino I, Yokoyama H, Yano T, et al. Skip metastasis to the mediastinal lymph nodes in non-small cell lung cancer. Ann Thorac Surg. 1996; 62: 10211025.
  • 12
    Bonner JA, Garces YI, Sawyer TE, et al. Frequency of noncontiguous lymph node involvement in patients with resectable nonsmall cell lung carcinoma. Cancer. 1999; 86: 11591164.
  • 13
    Little AG, DeHoyos A, Kirgan DM, Arcomano TR, Murray KD. Intraoperative lymphatic mapping for non-small cell lung cancer: the sentinel node technique. J Thorac Cardiovasc Surg. 1999; 117: 220224.
  • 14
    Doki Y, Ishikawa O, Mano M, et al. Cytokeratin deposits in lymph nodes show distinct clinical significance from lymph node micrometastasis in human esophageal cancers. J Surg Res. 2002; 107: 7581.
  • 15
    Izbicki JR, Hosch SB, Pichlmeier U, et al. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med. 1997; 337: 11881194.
  • 16
    Yasuda K, Adachi Y, Shiraishi N, Inomata M, Takeuchi H, Kitano S. Prognostic effect of lymph node micrometastasis in patients with histologically node-negative gastric cancer. Ann Surg Oncol. 2002; 9: 771774.
  • 17
    Hainsworth PJ, Tjandra JJ, Stillwell RG, et al. Detection and significance of occult metastases in node-negative breast cancer. Br J Surg. 1993; 80: 459463.
  • 18
    Jiao X, Krasna MJ. Clinical significance of micrometastasis in lung and esophageal cancer: a new paradigm in thoracic oncology. Ann Thorac Surg. 2002; 74: 278284.
  • 19
    Maruyama R, Sugio K, Mitsudomi T, Saitoh G, Ishida T, Sugimachi K. Relationship between early recurrence and micrometastases in the lymph nodes of patients with Stage I non-small-cell lung cancer. J Thorac Cardiovasc Surg. 1997; 114: 535543.
  • 20
    Ohgami A, Mitsudomi T, Sugio K, et al. Micrometastatic tumor cells in the bone marrow of patients with non-small cell lung cancer. Ann Thorac Surg. 1997; 64: 363367.
  • 21
    Dobashi K, Sugio K, Osaki T, Oka T, Yasumoto K. Micrometastatic P53-positive cells in the lymph nodes of non-small-cell lung cancer: prognostic significance. J Thorac Cardiovasc Surg. 1997; 114: 339346.
  • 22
    Gu CD, Osaki T, Oyama T, et al. Detection of micrometastatic tumor cells in pN0 lymph nodes of patients with completely resected nonsmall cell lung cancer: impact on recurrence and survival. Ann Surg. 2002; 235: 133139.
  • 23
    Yeatman TJ, Cox CE. The significance of breast cancer lymph node micrometastases. Surg Oncol Clin North Am. 1999; 8: 481496.
  • 24
    Galea MH, Athanassiou E, Bell J, et al. Occult regional lymph node metastases from breast carcinoma: immunohistological detection with antibodies CAM 5.2 and NCRC-11. J Pathol. 1991; 165: 221227.
  • 25
    Oosterhuis JW, Theunissen PH, Bollen EC. Improved pre-operative mediastinal staging in non-small-cell lung cancer by serial sectioning and immunohistochemical staining of lymph-node biopsies. Eur J Cardiothorac Surg. 2001; 20: 335338.
  • 26
    Ambrosch P, Brinck U. Detection of nodal micrometastases in head and neck cancer by serial sectioning and immunostaining. Oncology. 1996; 10: 12211225.
  • 27
    Blaheta HJ, Schittek B, Breuninger H, et al. Detection of melanoma micrometastasis in sentinel nodes by reverse transcription-polymerase chain reaction correlates with tumor thickness and is predictive of micrometastatic disease in the lymph node basin. Am J Surg Pathol. 1999; 23: 822828.
  • 28
    Deguchi T, Doi T, Ehara H, et al. Detection of micrometastatic prostate cancer cells in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res. 1993; 53: 53505354.
  • 29
    Sanchez-Cespedes M, Esteller M, Hibi K, et al. Molecular detection of neoplastic cells in lymph nodes of metastatic colorectal cancer patients predicts recurrence. Clin Cancer Res. 1999; 5: 24502454.
  • 30
    Shariat SF, Roudier MP, Wilcox GE, et al. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. Cancer Res. 2003; 63: 46624670.
  • 31
    Blaheta HJ, Ellwanger U, Schittek B, et al. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol. 2000; 114: 637642.
  • 32
    Okegawa T, Nutahara K, Higashihara E. Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathological Stage T2 prostate cancer. J Urol. 2000; 163: 11831188.
  • 33
    Alexander A, Subramanian N, Buxbaum JN, Jacobson DR. Drop-in, drop-out allele-specific PCR: a highly sensitive, single-tube method. Mol Biotechnol. 2004; 28: 171174.
  • 34
    Eldadah ZA, Grifo JA, Dietz HC. Marfan syndrome as a paradigm for transcript-targeted preimplantation diagnosis of heterozygous mutations. Nat Med. 1995; 1: 798803.
  • 35
    Navidi W, Arnheim N, Waterman MS. A multiple-tubes approach for accurate genotyping of very small DNA samples by using PCR: statistical considerations. Am J Hum Genet. 1992; 50: 347359.
  • 36
    Osaki T, Oyama T, Gu CD, et al. Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely resected Stage I non-small-cell lung cancer. J Clin Oncol. 2002; 20: 29302936.
  • 37
    Johansson L, Andersson C, Albin M. Immunohistochemical study of 158 lung carcinomas. APMIS. 1992; 100: 914921.
  • 38
    Ramaekers F, Huysmans A, Schaart G, Moesker O, Vooijs P. Tissue distribution of keratin 7 as monitored by a monoclonal antibody. Exp Cell Res. 1987; 170: 235249.
  • 39
    Tan J, Sidhu G, Greco MA, Ballard H, Wieczorek R. Villin, cytokeratin 7, and cytokeratin 20 expression in pulmonary adenocarcinoma with ultrastructural evidence of microvilli with rootlets. Hum Pathol. 1998; 29: 390396.
  • 40
    Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000; 13: 962972.
  • 41
    Fukai I, Masaoka A, Hashimoto T, et al. Differential diagnosis of thymic carcinoma and lung carcinoma with the use of antibodies to cytokeratins. J Thorac Cardiovasc Surg. 1995; 110: 16701675.
  • 42
    Ross GL, Shoaib T, Scott J, Soutar DS, Gray HW, MacKie R. The learning curve for sentinel node biopsy in malignant melanoma. Br J Plast Surg. 2002; 55: 298301.
  • 43
    Classe JM, Curtet C, Campion L, et al. Learning curve for the detection of axillary sentinel lymph node in breast cancer. Eur J Surg Oncol. 2003; 29: 426433.
  • 44
    Salerno CT, Frizelle S, Niehans GA, et al. Detection of occult micrometastases in non-small cell lung carcinoma by reverse transcriptase-polymerase chain reaction. Chest. 1998; 113: 15261532.
  • 45
    D'Cunha J, Corfits AL, Herndon JE, et al. Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in Stage I non-small cell lung cancer—preliminary results of Cancer and Leukemia Group B Trial 9761. J Thorac Cardiovasc Surg. 2002; 123: 484491.
  • 46
    Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004; 350: 17131721.
  • 47
    Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004; 350: 351360.
  • 48
    Strauss GM, Herndon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) Protocol 9633 [abstract]. J Clin Oncol. 2004: 22(14S): A7019.